Veracyte, Inc. (VCYT)
| Market Cap | 2.66B |
| Revenue (ttm) | 517.15M |
| Net Income (ttm) | 66.35M |
| Shares Out | 79.46M |
| EPS (ttm) | 0.82 |
| PE Ratio | 40.77 |
| Forward PE | 20.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 886,255 |
| Open | 33.82 |
| Previous Close | 33.85 |
| Day's Range | 32.97 - 33.88 |
| 52-Week Range | 22.61 - 50.71 |
| Beta | 1.96 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+31.62%) |
| Earnings Date | May 5, 2026 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its n... [Read more]
Financial Performance
In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 31.62% from the latest price.
News
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 aft...
Veracyte Names Kevin Haas as Chief Development and Technology Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.
Veracyte Transcript: Leerink Global Healthcare Conference 2026
Management is focused on high-ROI products, maintaining a 25% EBITDA margin, and launching Prosigna and MRD platforms. Decipher and Afirma drive growth through evidence, share gains, and technology upgrades, while AI and data initiatives support future innovation. Prosigna and MRD launches are expected to build momentum beyond 2026.
Veracyte Transcript: 47th Annual Raymond James Institutional Investor Conference
The conference highlighted robust 2025 growth, with $517M revenue and strong adoption of Decipher and Afirma tests. Strategic launches in MRD and breast cancer, digital pathology integration, and international expansion are set to drive double-digit growth and maintain industry-leading margins in 2026.
Veracyte Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong revenue and volume growth, with Decipher and Afirma driving results and profitability exceeding targets. 2026 guidance calls for 10–13% revenue growth, continued investment in new product launches, and stable margins, supported by a robust cash position and expanding clinical evidence.
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December...
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCOGU--Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium.
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond Ja...
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and ful...
Veracyte Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted robust financial growth, industry-leading profitability, and a strong innovation pipeline, with Decipher and Afirma driving core business and new launches like True MRD and ProSigna set to expand market reach. Continued evidence generation and disciplined capital allocation underpin long-term growth.
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and f...
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcar...
Veracyte Transcript: Stephens Annual Investment Conference
Q3 saw strong revenue and margin growth, driven by robust testing volumes and operational efficiencies. Market penetration for key products continues to rise, with new launches and clinical evidence supporting future growth. Investments in innovation, digital pathology, and MRD are expected to sustain profitability and expand the portfolio.
Veracyte Transcript: Jefferies London Healthcare Conference 2025
Strong revenue and margin growth were driven by Decipher and Afirma test expansion, with robust evidence and guideline support fueling adoption. New product launches, including MRD and Prosigna, are planned for 2026, while international and research strategies continue to advance.
Veracyte Transcript: Wolfe Research Healthcare Conference 2025
Revenue and margins are expanding rapidly, driven by Decipher and Afirma, with both products still in early market penetration. New launches like MRD and Prosigna are planned for next year, focusing on evidence, reimbursement, and measured adoption. Digital pathology and ongoing innovation are expected to further support growth.
Veracyte Earnings Call Transcript: Q3 2025
Q3 2025 saw 14% revenue growth and record 30% adjusted EBITDA margin, driven by strong Decipher and Afirma test volumes. 2025 guidance was raised for both revenue and margin, with continued investment in pipeline and new product launches expected to sustain double-digit growth into 2026.
Veracyte Announces Third Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We...
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #AfirmaGRID--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating t...
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 ...
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral...
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a ...
Veracyte Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Decipher and Afirma are showing strong growth, with new product launches and expanded coverage driving performance. Strategic investments in data, innovation, and international markets support long-term growth, while profitability and capital allocation remain disciplined.
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 Americ...
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conf...
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces New Study in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer...